XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will ...

Analysts have recently evaluated XOMA Royalty and provided 12-month price targets. The average target is $119.2, accompanied ...

Short XOMA slightly under 29.28, target 25.85, stop loss @ 29.36 Check the time stamp on this data. Updated AI-Generated ...

H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...

XOMA Royalty Corporation is a royalty aggregator, but is riskier than larger rivals like Royalty Pharma due to its focus on less established molecules. Investment options include XOMAP with an 8. ...

XOMA (NASDAQ:XOMA – Get Free Report) had its price target cut by equities research analysts at HC Wainwright from $123.00 to $104.00 in a research note issued to investors on Monday,Benzinga reports.

Analysts' ratings for XOMA Royalty (NASDAQ:XOMA) over the last quarter vary from bullish to bearish, as provided by 5 analysts. Summarizing their recent assessments, the table below illustrates ...

XOMA Co. (NASDAQ:XOMAO – Get Free Report) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 2,500 shares, a drop of 34.2% ...

$XOMA insiders have traded $XOMA stock on the open market 10 times in the past 6 months. Of those trades, 4 have been purchases and 6 have been sales. Here’s a ...